Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
FBLG 
FibroBiologics, Inc. Common Stock (FBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.75
1 Year Target Price $8.75
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.51% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.16M USD | Price to earnings Ratio - | 1Y Target Price 8.75 |
Price to earnings Ratio - | 1Y Target Price 8.75 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 0.24 - 2.55 | Updated Date 12/6/2025 |
52 Weeks Range 0.24 - 2.55 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -115.62% | Return on Equity (TTM) -1292.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17599757 | Price to Sales(TTM) - |
Enterprise Value 17599757 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 61292447 | Shares Floating 43209212 |
Shares Outstanding 61292447 | Shares Floating 43209212 | ||
Percent Insiders 11.73 | Percent Institutions 7.74 |
Upturn AI SWOT
FibroBiologics, Inc. Common Stock
Company Overview
History and Background
FibroBiologics, Inc. is a biotechnology company focused on the development of innovative cell-based therapies for chronic diseases. Founded in 2013, the company leverages its expertise in fibroblast biology to develop therapies for unmet medical needs.
Core Business Areas
- Segment Name 1: FibroGenesis: Develops and manufactures human fibroblasts for research and therapeutic use.
- Segment Name 2: Cell Therapies: Focuses on developing cell-based therapies targeting degenerative disc disease, cancer and other conditions.
Leadership and Structure
Dr. Pete O'Heeron is the CEO and Chairman. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Product Name 1: FibroGenesis Fibroblasts: Human fibroblasts used in research and therapeutic applications. Market share is difficult to ascertain precisely due to the fragmented nature of the cell therapy market. Competitors include Lonza and Thermo Fisher Scientific.
- Product Name 2: Cell-Based Therapies (Pipeline): Developing therapies for degenerative disc disease, cancer, and other conditions. Currently in clinical trials, no market share yet. Competitors include disc-regenerating therapies from companies like DiscGenics, and cell therapy products from Bluebird Bio.
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing field, driven by advances in regenerative medicine and personalized healthcare. It is characterized by high innovation, regulatory complexity, and significant unmet medical needs.
Positioning
FibroBiologics is positioned as an innovator in fibroblast-based therapies, leveraging its proprietary technology to address chronic diseases. Its competitive advantage lies in its focus on fibroblast biology and potential for novel therapeutic applications.
Total Addressable Market (TAM)
The TAM for cell-based therapies is projected to reach billions of dollars in the coming years. FibroBiologics is targeting specific segments of this market, including degenerative disc disease and cancer, aiming to capture a significant share through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary fibroblast technology platform
- Experienced management team
- Strong focus on unmet medical needs
- Pipeline of cell-based therapies
Weaknesses
- Limited revenue generation
- High reliance on research and development funding
- Clinical trial risks and uncertainties
- Relatively small company size
Opportunities
- Expanding applications of fibroblast technology
- Strategic partnerships and collaborations
- Positive clinical trial results
- Growing demand for cell-based therapies
Threats
- Regulatory hurdles and delays
- Competition from established players
- Technological advancements by competitors
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
Competitive Landscape
Competitive landscape analysis is challenging due to FibroBiologics' private status and the evolving cell therapy market. The company competes with both established pharmaceutical companies and emerging biotechnology firms.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's private status. Growth is primarily driven by research and development progress.
Future Projections: Future projections are dependent on clinical trial outcomes and regulatory approvals. Analyst estimates are not currently available.
Recent Initiatives: Recent initiatives include advancing cell-based therapies into clinical trials and expanding the FibroGenesis product line.
Summary
FibroBiologics is a biotechnology company focused on fibroblast-based cell therapies with a promising pipeline targeting unmet medical needs. The company's strengths lie in its proprietary technology, but it faces challenges related to funding, clinical trial risks, and competition. Future success depends on positive clinical trial outcomes, strategic partnerships, and regulatory approvals. Given its position, it is positioned as a high risk, high reward company that needs to focus on raising funds and scaling successfully.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Press Releases
Disclaimers:
This analysis is based on limited publicly available information and should not be considered investment advice. The information provided is for informational purposes only and does not constitute a solicitation to buy or sell securities.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroBiologics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-01-31 | Founder, Chairperson & CEO Mr. Peter O'Heeron | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.fibrobiologics.com |
Full time employees 13 | Website https://www.fibrobiologics.com | ||
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.